Showing results (101-110 of 4,543) with videos related to
Sort By:
Pageof 455
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|January 11, 2024
SERS probing of fungal HET-s fibrils formed at neutral and acidic pH conditionsMin Wu, Jose Miguel Flores-Fernandez, YongLiang Wang, et al.The Journal of Infectious Diseases|January 3, 2018
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free RegimensMaria Stepanova, Alexander Thompson, Joseph Doyle, et al.The American Journal of Managed Care|April 10, 2020
Outcomes of liver transplantation by insurance types in the United StatesMaria Stepanova, Saleh Al Qahtani, Alita Mishra, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2021
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of LifeZobair M Younossi, Maria Stepanova, Rebecca A Taub, et al.Journal of Hepatology|January 29, 2024
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver diseaseZobair M Younossi, James M Paik, Maria Stepanova, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2021
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United StatesZobair M Younossi, Michael Harring, Youssef Younossi, et al.Gut|August 2, 2019
Epidemiology of chronic liver diseases in the USA in the past three decadesZobair M Younossi, Maria Stepanova, Youssef Younossi, et al.Hepatology Communications|February 27, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisZobair M Younossi, Fatema Nader, Dominic Labriola, et al.Medicine|November 3, 2012
Nonalcoholic fatty liver disease in lean individuals in the United StatesZobair M Younossi, Maria Stepanova, Francesco Negro, et al.Gastro Hep Advances|July 22, 2025
Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D InstrumentsZobair M Younossi, Maria Stepanova, Yestle Kim, et al.Pageof 455